Cargando…
Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer
PURPOSE: Tryptophan metabolites have immunomodulatory functions, suggesting possible roles in cancer immunity. METHODS: Plasma tryptophan metabolites were measured using liquid chromatography/mass spectrometry before immune checkpoint inhibitors (ICIs) in patients with non-small cell lung cancer (NS...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854397/ https://www.ncbi.nlm.nih.gov/pubmed/32533317 http://dx.doi.org/10.1007/s12094-020-02421-8 |
_version_ | 1783646079628083200 |
---|---|
author | Karayama, M. Masuda, J. Mori, K. Yasui, H. Hozumi, H. Suzuki, Y. Furuhashi, K. Fujisawa, T. Enomoto, N. Nakamura, Y. Inui, N. Suda, T. Maekawa, M. Sugimura, H. Takada, A. |
author_facet | Karayama, M. Masuda, J. Mori, K. Yasui, H. Hozumi, H. Suzuki, Y. Furuhashi, K. Fujisawa, T. Enomoto, N. Nakamura, Y. Inui, N. Suda, T. Maekawa, M. Sugimura, H. Takada, A. |
author_sort | Karayama, M. |
collection | PubMed |
description | PURPOSE: Tryptophan metabolites have immunomodulatory functions, suggesting possible roles in cancer immunity. METHODS: Plasma tryptophan metabolites were measured using liquid chromatography/mass spectrometry before immune checkpoint inhibitors (ICIs) in patients with non-small cell lung cancer (NSCLC). RESULTS: The 19 patients with NSCLC had significantly lower levels of tryptophan (p = 0.002) and xanthurenic acid (p = 0.032), and a significantly higher level of 3-hydroxyanthranilic acid (3-HAA) (p = 0.028) compared with the 10 healthy volunteers. The patients achieving objective responses had significantly lower levels of 3-HAA than those who did not (p = 0.045). Receiver operating characteristic analyses determined that the cutoff value of 3-HAA for objective response was 35.4 pmol/mL (sensitivity: 87.5% and specificity: 83.3%). The patients with 3-HAA < 35.4 pmol/mL had significantly longer median progression-free survival (7.0 months) than those without (1.6 months, p = 0.022). CONCLUSIONS: Tryptophan metabolites may have a potential for predicting the efficacy of ICIs. REGISTRATION NUMBER: University Hospital Medical Information Network Clinical Trial Registry 000026140. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12094-020-02421-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7854397 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-78543972021-02-08 Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer Karayama, M. Masuda, J. Mori, K. Yasui, H. Hozumi, H. Suzuki, Y. Furuhashi, K. Fujisawa, T. Enomoto, N. Nakamura, Y. Inui, N. Suda, T. Maekawa, M. Sugimura, H. Takada, A. Clin Transl Oncol Brief Research Article PURPOSE: Tryptophan metabolites have immunomodulatory functions, suggesting possible roles in cancer immunity. METHODS: Plasma tryptophan metabolites were measured using liquid chromatography/mass spectrometry before immune checkpoint inhibitors (ICIs) in patients with non-small cell lung cancer (NSCLC). RESULTS: The 19 patients with NSCLC had significantly lower levels of tryptophan (p = 0.002) and xanthurenic acid (p = 0.032), and a significantly higher level of 3-hydroxyanthranilic acid (3-HAA) (p = 0.028) compared with the 10 healthy volunteers. The patients achieving objective responses had significantly lower levels of 3-HAA than those who did not (p = 0.045). Receiver operating characteristic analyses determined that the cutoff value of 3-HAA for objective response was 35.4 pmol/mL (sensitivity: 87.5% and specificity: 83.3%). The patients with 3-HAA < 35.4 pmol/mL had significantly longer median progression-free survival (7.0 months) than those without (1.6 months, p = 0.022). CONCLUSIONS: Tryptophan metabolites may have a potential for predicting the efficacy of ICIs. REGISTRATION NUMBER: University Hospital Medical Information Network Clinical Trial Registry 000026140. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12094-020-02421-8) contains supplementary material, which is available to authorized users. Springer International Publishing 2020-06-12 2021 /pmc/articles/PMC7854397/ /pubmed/32533317 http://dx.doi.org/10.1007/s12094-020-02421-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Brief Research Article Karayama, M. Masuda, J. Mori, K. Yasui, H. Hozumi, H. Suzuki, Y. Furuhashi, K. Fujisawa, T. Enomoto, N. Nakamura, Y. Inui, N. Suda, T. Maekawa, M. Sugimura, H. Takada, A. Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer |
title | Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer |
title_full | Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer |
title_fullStr | Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer |
title_full_unstemmed | Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer |
title_short | Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer |
title_sort | comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer |
topic | Brief Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854397/ https://www.ncbi.nlm.nih.gov/pubmed/32533317 http://dx.doi.org/10.1007/s12094-020-02421-8 |
work_keys_str_mv | AT karayamam comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer AT masudaj comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer AT morik comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer AT yasuih comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer AT hozumih comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer AT suzukiy comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer AT furuhashik comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer AT fujisawat comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer AT enomoton comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer AT nakamuray comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer AT inuin comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer AT sudat comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer AT maekawam comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer AT sugimurah comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer AT takadaa comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer |